The SPI1r subtype expressed an immunophenotype that was similar to that reported for LYL1 dysregulation and included low expression of T-cell related markers (CD1a, CD2, CD3e, CD4, and CD8a) and high expression of the myeloid marker CD33, potentially indicating intensive upfront chemotherapy like that required for ETP-ALL is warranted [14]. The gene discussed is CD33; the disease is acute lymphoblastic leukemia.